Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Express Scripts
Moodys
Harvard Business School
McKinsey

Last Updated: June 27, 2022

Nitisinone - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for nitisinone and what is the scope of patent protection?

Nitisinone is the generic ingredient in three branded drugs marketed by Novitium Pharma, Swedish Orphan, and Cycle Pharms Ltd, and is included in four NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Nitisinone has thirty-seven patent family members in twenty-five countries.

There are two drug master file entries for nitisinone. Four suppliers are listed for this compound.

Summary for nitisinone
International Patents:37
US Patents:2
Tradenames:3
Applicants:3
NDAs:4
Drug Master File Entries: 2
Finished Product Suppliers / Packagers: 4
Raw Ingredient (Bulk) Api Vendors: 109
Clinical Trials: 16
Patent Applications: 906
What excipients (inactive ingredients) are in nitisinone?nitisinone excipients list
DailyMed Link:nitisinone at DailyMed
Recent Clinical Trials for nitisinone

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sutphin DrugsN/A
Cycle Pharmaceuticals Ltd.Phase 1
ParexelPhase 1

See all nitisinone clinical trials

US Patents and Regulatory Information for nitisinone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novitium Pharma NITISINONE nitisinone CAPSULE;ORAL 211041-002 Aug 26, 2019 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Swedish Orphan ORFADIN nitisinone CAPSULE;ORAL 021232-002 Jan 18, 2002 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Swedish Orphan ORFADIN nitisinone SUSPENSION;ORAL 206356-001 Apr 22, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Cycle Pharms Ltd NITYR nitisinone TABLET;ORAL 209449-003 Jul 26, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Novitium Pharma NITISINONE nitisinone CAPSULE;ORAL 211041-001 Aug 26, 2019 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Swedish Orphan ORFADIN nitisinone CAPSULE;ORAL 021232-001 Jan 18, 2002 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Swedish Orphan ORFADIN nitisinone CAPSULE;ORAL 021232-003 Jan 18, 2002 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for nitisinone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Swedish Orphan ORFADIN nitisinone CAPSULE;ORAL 021232-002 Jan 18, 2002 See Plans and Pricing See Plans and Pricing
Swedish Orphan ORFADIN nitisinone CAPSULE;ORAL 021232-003 Jan 18, 2002 See Plans and Pricing See Plans and Pricing
Swedish Orphan ORFADIN nitisinone CAPSULE;ORAL 021232-001 Jan 18, 2002 See Plans and Pricing See Plans and Pricing
Swedish Orphan ORFADIN nitisinone CAPSULE;ORAL 021232-002 Jan 18, 2002 See Plans and Pricing See Plans and Pricing
Swedish Orphan ORFADIN nitisinone CAPSULE;ORAL 021232-003 Jan 18, 2002 See Plans and Pricing See Plans and Pricing
Swedish Orphan ORFADIN nitisinone CAPSULE;ORAL 021232-001 Jan 18, 2002 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for nitisinone

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
MendeliKABS Europe Ltd Nitisinone MDK (previously Nitisinone MendeliKABS) nitisinone EMEA/H/C/004281
Treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.
Authorised yes no no 2017-08-24
Cycle Pharmaceuticals (Europe) Ltd Nityr nitisinone EMEA/H/C/004582
Treatment of adult and paediatric patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
Authorised yes no no 2018-07-26
Swedish Orphan Biovitrum International AB Orfadin nitisinone EMEA/H/C/000555
Hereditary tyrosinemia type 1 (HT 1)Orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.Alkaptonuria (AKU)Orfadin is indicated for the treatment of adult patients with alkaptonuria (AKU).
Authorised no no no 2005-02-20
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for nitisinone

Country Patent Number Title Estimated Expiration
Denmark 3089740 See Plans and Pricing
Serbia 54632 TEČNA FARMACEUTSKA KOMPOZICIJA KOJA SADRŽI NITIZINON (LIQUID PHARMACEUTICAL COMPOSITION COMPRISING NITISINONE) See Plans and Pricing
Serbia 60551 FARMACEUTSKA KOMPOZICIJA (PHARMACEUTICAL COMPOSITION) See Plans and Pricing
Spain 2806739 See Plans and Pricing
Mexico 2013014567 COMPOSICION FARMACEUTICA LIQUIDA QUE COMPRENDE NITISINONA. (LIQUID PHARMACEUTICAL COMPOSITION COMPRISING NITISINONE.) See Plans and Pricing
New Zealand 618332 Liquid pharmaceutical composition comprising nitisinone See Plans and Pricing
Japan 6038132 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for nitisinone

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0591275 05C0024 France See Plans and Pricing PRODUCT NAME: NITISINONE; REGISTRATION NO/DATE: EU/1/04/303/001 20050221
0591275 SPC/GB05/030 United Kingdom See Plans and Pricing PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
0591275 C300198 Netherlands See Plans and Pricing PRODUCT NAME: NITISINONE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT; REGISTRATION NO/DATE: EU/1/04/303/001-003 20050201
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Medtronic
Boehringer Ingelheim
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.